About the Authors
- Michal Mielcarek
-
Affiliation Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
- Caroline L. Benn
-
Affiliation Neusentis, Pfizer Inc., Cambridge, United Kingdom
- Sophie A. Franklin
-
Affiliation Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
- Donna L. Smith
-
Affiliation Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
- Ben Woodman
-
Current address: Leeds Institute for Molecular Medicine. St. James's University Hospital, University of Leeds, Leeds, United Kingdom
Affiliation Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
- Paul A. Marks
-
Affiliation Cell Biology Program, Sloan-Kettering Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America
- Gillian P. Bates
-
* E-mail: gillian.bates@kcl.ac.uk
Affiliation Department of Medical and Molecular Genetics, King's College London, London, United Kingdom
Competing Interests
The authors have read the journal's policy and have the following conflicts: Memorial Sloan Kettering holds patents on SAHA, which they licensed to Aton Pharma in 2001. Aton Pharma was wholly acquired by Merck in 2004. PAM has a royalty interest in the license. CLB is an employee of Pfizer Inc. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: MM GPB. Performed the experiments: MM CLB SAF DLS BW. Analyzed the data: MM GPB. Contributed reagents/materials/analysis tools: PAM. Wrote the paper: MM GPB.